In a meta-analysis of 7 nonexperimental cohort studies, there was a positive, almost linear association with no evidence of a threshold between alcohol consumption at baseline and systolic blood pressure levels during follow-up in healthy persons.
A greater than 15 mmHg reduction in 24-h ambulatory systolic BP was reported with the two highest single doses of the siRNA therapeutic zilebesiran, targeting hepatic angiotensinogen synthesis, at month 3 compared with placebo in the KARDIA 1 phase 2 trial.
The 2023 European Society of Hypertension (ESH) guidelines for the management of arterial hypertension has been published.
In the PHYSIC trial, systolic blood pressure (SBP) response to 4 widely used antihypertensive drug classes varied considerably. Personalized treatment had the potential to lower SBP by 4.4 mmHg compared with a fixed drug choice.
A serial cross-sectional analysis using data of the NHANES database investigated whether the prevalence of CV risk factors among young US adults changed from 2009 to March 2020.
An analysis of 32,019 individuals showed stronger associations between triglyceride (TG) levels and hypertension, SBP , BMI, or waist circumference in those of European ancestry compared with West African ancestry with minimal or no influence by environmental context, contrary to the associations with T2DM or fasting glucose.
A pooled analysis of patients with established ASCVD showed a 10-year risk of recurrent ASCVD events of 20% and a lifetime risk of 54%. Theoretically, optimization of both lifestyle and medications could reduce both risks and add 7.3 event-free years.
In a post-hoc analysis of the ADVANCE trial, cumulative SBP load was a better predictor of the occurrence of MACE in patients with T2DM compared with other BP measures.
In a meta-analysis of pooled individual participant data from 5 double-blind placebo-controlled RCTs, antihypertensive treatment was associated with a lower dementia risk compared with placebo.
AHA 2022 By participating in a mindfulness-based program, individuals with elevated office blood pressure (BP) could lower their systolic BP by 4.5 mmHg within 6 months compared with enhanced usual care.
ACC 2022 Two analyses using data of four phase 3 trials show that treatment with bempedoic acid lowers LDL-c in patients with renal impairment and in patients with hypertension. In addition, the analyses showed that bempedoic acid was generally well tolerated in these patients.
ACC 2022 Prof. Tita shares the results of the CHAP trial, which showed that treatment of mild chronic hypertension in pregnant women to a BP goal <140/90 mmHg reduces adverse pregnancy outcomes and does not impair fetal growth.